Switch theme
Sign up to access all valuation multiples
Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company’s main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.
2006
9
LTM Revenue $1.2M
LTM EBITDA -$2.2M
$17.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Moberg Pharma has a last 12-month revenue (LTM) of $1.2M and a last 12-month EBITDA of -$2.2M.
In the most recent fiscal year, Moberg Pharma achieved revenue of $1.0M and an EBITDA of -$2.0M.
Moberg Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Moberg Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.2M | XXX | $1.0M | XXX | XXX | XXX |
| Gross Profit | $0.9M | XXX | $0.7M | XXX | XXX | XXX |
| Gross Margin | 72% | XXX | 64% | XXX | XXX | XXX |
| EBITDA | -$2.2M | XXX | -$2.0M | XXX | XXX | XXX |
| EBITDA Margin | -177% | XXX | -193% | XXX | XXX | XXX |
| EBIT | -$20.6M | XXX | -$33.5M | XXX | XXX | XXX |
| EBIT Margin | -1651% | XXX | -3311% | XXX | XXX | XXX |
| Net Profit | -$16.1M | XXX | -$26.3M | XXX | XXX | XXX |
| Net Margin | -1290% | XXX | -2600% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Moberg Pharma's stock price is SEK 9 (or $1).
Moberg Pharma has current market cap of SEK 437M (or $45.1M), and EV of SEK 172M (or $17.7M).
See Moberg Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $17.7M | $45.1M | XXX | XXX | XXX | XXX | $-0.34 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Moberg Pharma has market cap of $45.1M and EV of $17.7M.
Moberg Pharma's trades at 17.5x EV/Revenue multiple, and -9.1x EV/EBITDA.
Equity research analysts estimate Moberg Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Moberg Pharma has a P/E ratio of -2.8x.
See valuation multiples for Moberg Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $45.1M | XXX | $45.1M | XXX | XXX | XXX |
| EV (current) | $17.7M | XXX | $17.7M | XXX | XXX | XXX |
| EV/Revenue | 14.2x | XXX | 17.5x | XXX | XXX | XXX |
| EV/EBITDA | -8.1x | XXX | -9.1x | XXX | XXX | XXX |
| EV/EBIT | -0.9x | XXX | -0.5x | XXX | XXX | XXX |
| EV/Gross Profit | 19.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.8x | XXX | -1.7x | XXX | XXX | XXX |
| EV/FCF | -4.3x | XXX | -1.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMoberg Pharma's last 12 month revenue growth is 158%
Moberg Pharma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $3.8M for the same period.
Moberg Pharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Moberg Pharma's rule of X is 218% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Moberg Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 158% | XXX | 135% | XXX | XXX | XXX |
| EBITDA Margin | -177% | XXX | -193% | XXX | XXX | XXX |
| EBITDA Growth | -48% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | -35% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 218% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $3.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 73% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 3081% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 3376% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Moberg Pharma acquired XXX companies to date.
Last acquisition by Moberg Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Moberg Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Moberg Pharma founded? | Moberg Pharma was founded in 2006. |
| Where is Moberg Pharma headquartered? | Moberg Pharma is headquartered in Sweden. |
| How many employees does Moberg Pharma have? | As of today, Moberg Pharma has 9 employees. |
| Who is the CEO of Moberg Pharma? | Moberg Pharma's CEO is Ms. Anna Ljung. |
| Is Moberg Pharma publicy listed? | Yes, Moberg Pharma is a public company listed on STO. |
| What is the stock symbol of Moberg Pharma? | Moberg Pharma trades under MOB ticker. |
| When did Moberg Pharma go public? | Moberg Pharma went public in 2011. |
| Who are competitors of Moberg Pharma? | Similar companies to Moberg Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Moberg Pharma? | Moberg Pharma's current market cap is $45.1M |
| What is the current revenue of Moberg Pharma? | Moberg Pharma's last 12 months revenue is $1.2M. |
| What is the current revenue growth of Moberg Pharma? | Moberg Pharma revenue growth (NTM/LTM) is 158%. |
| What is the current EV/Revenue multiple of Moberg Pharma? | Current revenue multiple of Moberg Pharma is 14.2x. |
| Is Moberg Pharma profitable? | Yes, Moberg Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Moberg Pharma? | Moberg Pharma's last 12 months EBITDA is -$2.2M. |
| What is Moberg Pharma's EBITDA margin? | Moberg Pharma's last 12 months EBITDA margin is -177%. |
| What is the current EV/EBITDA multiple of Moberg Pharma? | Current EBITDA multiple of Moberg Pharma is -8.1x. |
| What is the current FCF of Moberg Pharma? | Moberg Pharma's last 12 months FCF is -$4.1M. |
| What is Moberg Pharma's FCF margin? | Moberg Pharma's last 12 months FCF margin is -329%. |
| What is the current EV/FCF multiple of Moberg Pharma? | Current FCF multiple of Moberg Pharma is -4.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
